天中依脉品牌怎么样 申请店铺

我要投票 天中依脉在医疗保健行业中的票数:550 更新时间:2025-04-18
天中依脉是哪个国家的品牌?公司简介: 天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业

外推网助力天中依脉品牌出海!通过在本页面挂载天中依脉品牌的产品链接和联系邮箱,可以提高天中依脉产品曝光!跨境电商爆单神器,目前只要100元/年哦~

天中依脉怎么样

公司简介:

天中依脉集团成立于2009年,现拥有三家全资子公司:天津市天中依脉科技开发有限公司、依脉人工智能医疗科技(天津)有限公司和汇汉依脉智能科技(上海)有限公司。公司坐落于天津滨海高新区华苑产业区,是我国专注于中医四诊客观化技术研究和中医诊疗设备的研发与制造的科技型国内知名高新企业之一。公司具有国内一流的中医诊疗仪器研发团队,完善的生产体系和检验设备,产品质量稳定可靠。公司的脉象仪,舌象仪等产品获得国家中医药管理局中医诊疗设备2011版第一批推荐品目。

天中依脉是较早专注于中医诊疗客观化的高新技术企业,核心技术脱胎于天津中医药大学、天津大学历届专家及从上世纪80年代开始的“中医客观化技术”研究。依脉人工智能医疗科技(天津)有限公司是天中依脉的全资子公司,致力于发展“中医云脑”智能化云中医服务,参与国家“一带一路”中医文化传播与技术推广,全面支持国家医联体建设、家庭医生签约服务等领域的中医药服务,践行健康中国战略。

 15625675637646365997938.png

2009年创立至今,天中依脉与国内三十余家高校及高级医疗机构建立了长期深入的科研合作关系,拥有200多项国家专利及软件著作等知识产权,产品服务于500余家医疗机构,成为中医智能行业的领航者。

公司荣誉:

●2009年,参与国家中医诊断仪器国际以及国家行业标准制定

●2009年,参与火星MARS500计划项目

●2011年,参与承担国家973项目

●2011年,舌象仪和脉象仪同时入选国家中医药管理局《中医诊疗设备推荐品目2011版第一批》

●2012年,参与国家自然基金项目

●2012年,参与国家十二五支撑项目

●2013年,获得中国科技部“科技型中小企业技术创新基金”

●2018年,天中依脉“智云中医”中医医联体管理、服务体系上市,并与全国多家中医机构建立合作关系。

公司愿景:

1、中医客观化诊疗技术,中医健康大数据和人工智能科技的国际领导品牌!

2、建立开放、共享、共赢的中医健康数据服务平台,打造中医健康产业生态群。

3、推动先进的中医科技和传统文化走向世界,服务全人类健康!

公司使命:

创新中医科技,传承中医文化,引领健康生活!

Company profile: Tianzhong Yimai group, founded in 2009, now has three wholly-owned subsidiaries: Tianjin Tianzhong Yimai Technology Development Co., Ltd., Yimai artificial intelligence medical technology (Tianjin) Co., Ltd. and Huihan Yimai Intelligent Technology (Shanghai) Co., Ltd. The company is located in Huayuan Industrial Zone, Binhai high tech Zone, Tianjin. It is one of the well-known high-tech enterprises in China, which focuses on the research and development and manufacturing of the four diagnosis and treatment objectification technology of traditional Chinese medicine and the diagnosis and treatment equipment of traditional Chinese medicine. The company has a domestic first-class R & D team of TCM diagnosis and treatment instruments, perfect production system and testing equipment, and stable and reliable product quality. The company's pulse instrument, tongue instrument and other products have won the first batch of recommended items of Chinese medicine diagnosis and treatment equipment 2011 edition of the State Administration of traditional Chinese medicine. Tianzhong Yimai is an early high-tech enterprise focusing on the objectification of TCM diagnosis and treatment. Its core technology was born from the experts of Tianjin University of traditional Chinese medicine, Tianjin University and the research on "objectification technology of TCM" since the 1980s. One belt, one road, China's Tianjin medical company (China) is a wholly-owned subsidiary of the Chinese medicine company. It is committed to the development of the "Yun Nao" intelligent Chinese medicine service, participating in the "one belt and one way" Chinese medicine culture dissemination and technology promotion, and fully supporting the traditional Chinese medicine service in the fields of national medical conjoined construction, family doctor's contract service and so on, and practicing the healthy China strategy. Since its establishment in 2009, Tianzhong Yimai has established a long-term and in-depth scientific research cooperation relationship with more than 30 universities and advanced medical institutions in China. It has more than 200 national patents and software works and other intellectual property rights. Its products serve more than 500 medical institutions and become a leader in the intelligent industry of traditional Chinese medicine. Honors of the company: ● in 2009, participated in the development of international and national industry standards for diagnostic instruments of traditional Chinese medicine ● in 2009, participated in Mars Mars 500 program project ● in 2011, participated in the national 973 project ● in 2011, tongue imager and pulse imager were selected into the first batch of recommended items of Chinese medical diagnosis and treatment equipment 2011 edition by the State Administration of traditional Chinese medicine ● in 2012, participated in the national natural fund project ● 201 2 years, participated in the national 12th Five Year Plan support project ● in 2013, won the "technology innovation fund for small and medium-sized enterprises of science and technology type" of the Ministry of science and technology of China ● in 2018, Tianzhong Yimai "Zhiyun TCM" TCM management and service system went public, and established cooperation with many TCM institutions across the country. Company vision: 1. Objective diagnosis and treatment technology of traditional Chinese medicine, international leading brand of health big data and artificial intelligence technology of traditional Chinese medicine! 2. Establish an open, shared and win-win TCM health data service platform, and build an ecosystem of TCM health industry. 3. Promote the advanced technology of traditional Chinese medicine and traditional culture to the world, and serve the health of all mankind! Mission of the company: innovate TCM technology, inherit TCM culture and lead healthy life!

本文链接: https://brand.waitui.com/93449407c.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

张裕A:拟回购1000万股至1500万股B股股份

36氪获悉,张裕A发布公告,公司拟回购已发行的境内上市外资股(B股)并予以注销,拟回购股份数量为不低于1000万股,不超过1500万股,拟回购资金总额不超过人民币1亿元,拟回购价格不超过港币11.5元/股。

2小时前

2025数据安全发展大会即将举行,“数据要素×”大赛温州站启动报名

36氪获悉,2025数据安全发展大会将于5月16-18日举行。本届大会由温州市人民政府主办,温州市数据局、瓯海区人民政府等单位承办,赛迪研究院(赛迪集团)、浙江大学计算机科学与技术学院、世界青年科学家联合会协办,以“瓯江论数·数安未来”为主题。本届大会同期还将举办“数据要素×”大赛温州站比赛,现已启动报名。在全国统一的13个赛道基础上,温州站还增设智慧教育、安全治理、安全保障、合规流通、智能体等多个特色赛道。

2小时前

杭叉集团:2024年净利润20.22亿元,同比增长17.86%

36氪获悉,杭叉集团发布公告,2024年实现营业收入164.86亿元,同比增长1.15%;归属于上市公司股东的净利润20.22亿元,同比增长17.86%;基本每股收益1.54元。公司拟向全体股东每10股派发现金红利5元(含税)。

2小时前

居然智家:公司实际控制人、董事长兼CEO被留置

36氪获悉,居然智家发布公告,公司收到实际控制人、董事长兼CEO汪林朋家属通知,汪林朋近日收到武汉市江汉区监察委员会签发的《留置通知书》和《立案通知书》。目前公司其他董事、监事和高级管理人员均正常履职,控制权未发生变化。公司经营情况一切正常,不会对日常经营活动产生重大影响。公司将持续关注事项进展并及时履行信息披露义务。

2小时前

霸王茶姬正式登陆纳斯达克,开盘涨超20.53%

36氪获悉,霸王茶姬正式登陆纳斯达克。上市首日开盘涨超20.53%,报33.75美元。根据发行价28美元测算,此次IPO募资规模为4.11亿美元。今年3月6日,中国证监会国际合作司披露了《关于Chagee Holdings Limited(茶姬控股有限公司)境外发行上市备案通知书》,霸王茶姬成为中国证监会启动境外上市备案制度以来,第89家通过备案的拟赴美上市的企业。获得证监会备案许可后,霸王茶姬于3月26日凌晨公开递交了招股书。据招股书信息,此次IPO募集的资金,将用于用于科技投入、新品研发、扩大门店规模、构建海外供应链网络等。

2小时前

本页详细列出关于MCKESSON麦克森的品牌信息,含品牌所属公司介绍,MCKESSON麦克森所处行业的品牌地位及优势。
咨询